Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2019

Open Access 01-09-2019 | Ovarian Cancer | Gynecologic Oncology

Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome

Authors: Marcia Hall, MD, PhD, Konstantinos Savvatis, MD, PhD, Katherine Nixon, MD, Maria Kyrgiou, MD, PhD, Kuhan Hariharan, MD, Malcolm Padwick, MD, Owen Owens, MD, Paula Cunnea, MD, PhD, Jeremy Campbell, MD, Alan Farthing, MD, Richard Stumpfle, MD, Ignacio Vazquez, MD, Neale Watson, MD, Jonathan Krell, MD, PhD, Hani Gabra, MD, PhD, Gordon Rustin, MD, PhD, Christina Fotopoulou, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2019

Login to get access

Abstract

Background

This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC).

Methods

A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival.

Results

The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04–2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15–3.13), and palliation alone (HR, 3.43; 95% CI 1.51–7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors.

Conclusions

Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone.
Literature
1.
go back to reference Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Am J Obstet Gynecol. 2006;107:77–85.CrossRef Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Am J Obstet Gynecol. 2006;107:77–85.CrossRef
2.
go back to reference Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33:937–43.CrossRefPubMedPubMedCentral Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33:937–43.CrossRefPubMedPubMedCentral
3.
go back to reference Fotopoulou C, Sehouli J, Aletti G, et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol. 2017;35:587–90.CrossRefPubMed Fotopoulou C, Sehouli J, Aletti G, et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol. 2017;35:587–90.CrossRefPubMed
4.
go back to reference Tseng JH, Cowan RA, Zhou Q, et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol. 2018;151:24–31.CrossRefPubMed Tseng JH, Cowan RA, Zhou Q, et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol. 2018;151:24–31.CrossRefPubMed
5.
go back to reference Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRefPubMed
6.
go back to reference Fotopoulou C, Jones BP, Savvatis K, et al. Maximal-effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet. 2016;294:607–14.CrossRefPubMed Fotopoulou C, Jones BP, Savvatis K, et al. Maximal-effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet. 2016;294:607–14.CrossRefPubMed
7.
go back to reference Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015;137:553–8.CrossRefPubMedPubMedCentral Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015;137:553–8.CrossRefPubMedPubMedCentral
8.
go back to reference Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208:614–20.CrossRefPubMed Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208:614–20.CrossRefPubMed
9.
go back to reference Sundar S, Kumar S, Long J, et.al. Patient-reported outcomes after surgery in advanced ovarian cancer: initial results from the international, prospective, multicentre SOCQER 2 study. In: 17th Biennial meeting of the international Gynecologic Cancer Society Kyoto, Japan, 14–16 Sept 2018 (abstract 034). https://dx.doi.org/10.1136/00009577-201809002-00001. Sundar S, Kumar S, Long J, et.al. Patient-reported outcomes after surgery in advanced ovarian cancer: initial results from the international, prospective, multicentre SOCQER 2 study. In: 17th Biennial meeting of the international Gynecologic Cancer Society Kyoto, Japan, 14–16 Sept 2018 (abstract 034). https://​dx.​doi.​org/​10.​1136/​00009577-201809002-00001.
10.
go back to reference Phillips A, Balega J, Nevin J, Singh K, Elattar A, Kehoe S, et al. Reporting “denominator” data is essential for benchmarking and quality standards in ovarian cancer. Gynecol Oncol. 2017;146:94–100.CrossRefPubMed Phillips A, Balega J, Nevin J, Singh K, Elattar A, Kehoe S, et al. Reporting “denominator” data is essential for benchmarking and quality standards in ovarian cancer. Gynecol Oncol. 2017;146:94–100.CrossRefPubMed
11.
go back to reference Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26:1354–63.CrossRefPubMed Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26:1354–63.CrossRefPubMed
12.
go back to reference Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.CrossRefPubMed Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.CrossRefPubMed
13.
go back to reference Fotopoulou C, Hall M, Cruickshank D. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–39.CrossRefPubMed Fotopoulou C, Hall M, Cruickshank D. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–39.CrossRefPubMed
14.
go back to reference Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63.CrossRefPubMed Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63.CrossRefPubMed
15.
go back to reference Clamp A, McNeish I, Dean A, et al. ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Program and abstracts of the European Society for Medical Oncology 2017 Congress, 8–12 Sept 2017, Madrid, Spain (abstract 929O_PR). Clamp A, McNeish I, Dean A, et al. ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Program and abstracts of the European Society for Medical Oncology 2017 Congress, 8–12 Sept 2017, Madrid, Spain (abstract 929O_PR).
16.
go back to reference Barclay M, Gildea C, Poole J, et al. Factors affecting short-term mortality in women with ovarian, tubal, or primary peritoneal cancer: population-based cohort analysis of English National Cancer Registration Data. Int J Gynecol Cancer. 2016;26:56–65.CrossRefPubMed Barclay M, Gildea C, Poole J, et al. Factors affecting short-term mortality in women with ovarian, tubal, or primary peritoneal cancer: population-based cohort analysis of English National Cancer Registration Data. Int J Gynecol Cancer. 2016;26:56–65.CrossRefPubMed
17.
go back to reference Thrall M, Gray H, Symons R, Weiss NS, et al. Trends in treatment of advanced epithelial ovarian cancer in the medicare population. Gynecol Oncol. 2011;122:100–6.CrossRefPubMedPubMedCentral Thrall M, Gray H, Symons R, Weiss NS, et al. Trends in treatment of advanced epithelial ovarian cancer in the medicare population. Gynecol Oncol. 2011;122:100–6.CrossRefPubMedPubMedCentral
18.
go back to reference Shalowitz D, Epstein A, Ko E, et al. 2nd Nonsurgical management of ovarian cancer: prevalence and implications. Gynecol Oncol. 2016;142:30–7.CrossRefPubMed Shalowitz D, Epstein A, Ko E, et al. 2nd Nonsurgical management of ovarian cancer: prevalence and implications. Gynecol Oncol. 2016;142:30–7.CrossRefPubMed
19.
go back to reference Chiva LM, Mínguez J, Querleu D, et al. European surgical education and training in gynecologic oncology: the impact of an accredited fellowship. Int J Gynecol Cancer. 2017;27:819–25.CrossRefPubMed Chiva LM, Mínguez J, Querleu D, et al. European surgical education and training in gynecologic oncology: the impact of an accredited fellowship. Int J Gynecol Cancer. 2017;27:819–25.CrossRefPubMed
20.
go back to reference Barber EL, Rossi EC, Gehrig PA. Surgical readmission and survival in women with ovarian cancer: are short-term quality metrics incentivizing decreased long-term survival? Gynecol Oncol. 2017;147:607–11.CrossRefPubMedPubMedCentral Barber EL, Rossi EC, Gehrig PA. Surgical readmission and survival in women with ovarian cancer: are short-term quality metrics incentivizing decreased long-term survival? Gynecol Oncol. 2017;147:607–11.CrossRefPubMedPubMedCentral
21.
go back to reference Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol Oncol. 2009;112(1):16–21.CrossRefPubMed Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol Oncol. 2009;112(1):16–21.CrossRefPubMed
22.
go back to reference Clark RM, Rice LW, Del Carmen MG. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review. Gynecol Oncol. 2018;150:370–7.CrossRefPubMed Clark RM, Rice LW, Del Carmen MG. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review. Gynecol Oncol. 2018;150:370–7.CrossRefPubMed
23.
24.
go back to reference Soo Hoo S, Marriott N, Houlton A, et al. Patient-reported outcomes after extensive (ultraradical) surgery for ovarian cancer: results from a prospective longitudinal feasibility study. Int J Gynecol Cancer. 2015;25:1599–607.CrossRefPubMed Soo Hoo S, Marriott N, Houlton A, et al. Patient-reported outcomes after extensive (ultraradical) surgery for ovarian cancer: results from a prospective longitudinal feasibility study. Int J Gynecol Cancer. 2015;25:1599–607.CrossRefPubMed
25.
go back to reference Mahner S, Heitz F, Burges A, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO OVAR OP7). JCO. 2017;35:15(Suppl):TPS5602–TPS5602.CrossRef Mahner S, Heitz F, Burges A, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO OVAR OP7). JCO. 2017;35:15(Suppl):TPS5602–TPS5602.CrossRef
Metadata
Title
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
Authors
Marcia Hall, MD, PhD
Konstantinos Savvatis, MD, PhD
Katherine Nixon, MD
Maria Kyrgiou, MD, PhD
Kuhan Hariharan, MD
Malcolm Padwick, MD
Owen Owens, MD
Paula Cunnea, MD, PhD
Jeremy Campbell, MD
Alan Farthing, MD
Richard Stumpfle, MD
Ignacio Vazquez, MD
Neale Watson, MD
Jonathan Krell, MD, PhD
Hani Gabra, MD, PhD
Gordon Rustin, MD, PhD
Christina Fotopoulou, MD, PhD
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07516-3

Other articles of this Issue 9/2019

Annals of Surgical Oncology 9/2019 Go to the issue